Diagnosis and Pharmacotherapy of Chronic Obstructive Pulmonary Disease
Literature Review
DOI:
https://doi.org/10.55175/cdk.v52i10.1682Keywords:
Bronchodilator, diagnosis, pharmacotherapy, chronic obstructive pulmonary disease, COPDAbstract
Chronic obstructive pulmonary disease (COPD) is a lung disease with chronic respiratory symptoms and exacerbations that can be prevented and treated. COPD is characterized by airfow obstruction that is not fully reversible, generally due to long-term exposure to cigarette smoke, pollution, or other environmental risk factors. Multiaspect COPD assessment after confrmation of COPD diagnosis is needed to guide treatment. The diagnosis is established by spirometry and clinical evaluation, including assessment of symptoms, history of exacerbations, blood eosinophil levels, and the presence of comorbidities. COPD pharmacotherapy aims to reduce symptoms, reduce the risk of exacerbations, and improve the patient’s quality of life. Pharmacotherapy is administered during stable conditions or during exacerbations using bronchodilators alone or in combination, corticosteroids, and other supportive medications according to the patient’s needs, abilities, and condition. Personalized therapy based on symptom severity, history of exacerbations, and patient response. Regular monitoring, proper inhaler technique, and treatment adherence are essential for achieving optimal clinical outcomes.
Downloads
References
WHO. Chronic obstructive pulmonary disease (COPD) [Internet]. Geneva: WHO; 2023 [cited 2024 June 25]. Available from: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd).
Global Initiative for Chronic Obstructive Lung Disease [Internet]. United States: Global Initiative for Chronic Obstructive Lung Disease; 2024 [cited 2024 June 25]. Available from: https://goldcopd.org/2024-gold-report/.
PDPI. Pedoman diagnosis dan penatalaksanaan PPOK 2023 [Internet]. Jakarta: Perhimpunan Dokter Paru Indonesia; 2023 [cited 2024 June 25]. Available from: https://bukupdpi.klikpdpi.com/wp-content/uploads/2023/08/Dummy-Buku-PPOK-2023.pdf.
Widyawati. Merokok, penyebab utama penyakit paru obstruktif kronis [Internet]. Jakarta: Kemenkes; 2021 [cited 2024 June 25]. Available from: https://kemkes.go.id/id/merokok-penyebab-utama-penyakit-paru-obstruktif-kronis.
Medscape. Chronic obstructive pulmonary disease (COPD) [Internet]. Jakarta: Kemenkes; 2022 [cited 2024 June 25]. Available from: https://bukupdpi.klikpdpi.com/wp-content/uploads/2023/08/Dummy-Buku-PPOK-2023.pdf.
Tarmizi SN. Perokok aktif di Indonesia tembus 70 juta orang, mayoritas anak muda [Internet]. Jakarta: Kemenkes; 2024 [cited 2024 June 25]. Available from: http://kemkes.go.id/id/perokok-aktif-di-indonesia-tembus-70-juta-orang-mayoritas-anak-muda.
Appleton S, Jones T, Poole P, Pilotto L, Adams R, Lasserson TJ, et al. Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;2006(2):CD001387. doi: 10.1002/14651858.CD001387.
Burkes RM, Panos RJ. Ultra long-acting β-agonists in chronic obstructive pulmonary disease. J Exp Pharmacol. 2020;12:589-602. doi: 10.2147/JEP.S259328.
Vanfeteren L, Fabbri LM, Papi A, Petruzzelli S, Celli B. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal. Int J Chron Obstruct Pulmon Dis. 2018;13:3971-81. doi: 10.2147/COPD.S185975.
Maltais F, Bjermer L, Kerwin EM, Jones PW, Watkins ML, Tombs L, et al. Efcacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. Respir Res. 2019;20(1):238. doi: 10.1186/s12931-019-1193-9.
Vestbo J, Anderson JA, Brook RD, Calverley PM, Celli BR, Crim C, et al; SUMMIT Investigators. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet 2016;387(10030):1817-26. doi: 10.1016/S0140-6736(16)30069-1.
Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al; TORCH investigators. Salmeterol and futicasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775-89. doi: 10.1056/NEJMoa063070.
Renkema TE, Schouten JP, Koëter GH, Postma DS. Efects of long-term treatment with corticosteroids in COPD. Chest 1996;109(5):1156-62. doi: 10.1378/chest.109.5.1156.
Rice KL, Rubins JB, Lebahn F, Parenti CM, Duane PG, Kuskowski M, et al. Withdrawal of chronic systemic corticosteroids in patients with COPD: a randomized trial. Am J Respir Crit Care Med. 2000;162(1):174-8. doi: 10.1164/ajrccm.162.1.9909066.
Rogliani P, Matera MG, Page C, Puxeddu E, Cazzola M, Calzetta L. Efcacy and safety profle of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine. Respir Res. 2019;20(1):104. doi: 10.1186/s12931-019-1078-y.
Poole P, Sathananthan K, Fortescue R. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2019;5(5):CD001287. doi: 10.1002/14651858.CD001287.
Dal Negro RW, Wedzicha JA, Iversen M, Fontana G, Page C, Cicero AF, et al; RESTORE group; RESTORE study. Efect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. Eur Respir J. 2017;50(4):1700711. doi: 10.1183/13993003.00711-2017.
Cazzola M, Calzetta L, Page C, Jardim J, Chuchalin AG, Rogliani P, et al. Infuence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. Eur Respir Rev. 2015;24(137):451-61. doi: 10.1183/16000617.00002215.
Ram FS, Jones PW, Castro AA, De Brito JA, Atallah AN, Lacasse Y, et al. Oral theophylline for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002;2002(4):CD003902. doi: 10.1002/14651858.CD003902.
ZuWallack RL, Mahler DA, Reilly D, Church N, Emmett A, Rickard K, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001;119(6):1661-70. doi: 10.1378/chest.119.6.1661.
Cosio BG, Shafek H, Iglesias A, Yanez A, Cordova R, Palou A, et al. Oral low-dose theophylline on top of inhaled futicasone-salmeterol does not reduce exacerbations in patients with severe COPD: a pilot clinical trial. Chest 2016;150(1):123-30. doi: 10.1016/j.chest.2016.04.011.
Devereux G, Cotton S, Fielding S, McMeekin N, Barnes PJ, Briggs A, et al. Efect of theophylline as adjunct to inhaled corticosteroids on exacerbations in patients with COPD: a randomized clinical trial. JAMA. 2018;320(15):1548-59. doi: 10.1001/jama.2018.14432.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Johan Indra Lukito
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
